Is Tocilizumab an Effective Option for Treatment of Refractory Uveitis Associated with Juvenile Idiopathic Arthritis?
Authors:
- Christoph TappeinerCTChristoph Tappeiner
- Carsten HeinzCHCarsten Heinz
- Gerd GanserGGGerd Ganser
- Arnd HeiligenhausAHArnd Heiligenhaus
Open Access
- 1 June 2012
- journal article
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 39 (6) , 1294.2-1295
Abstract
To the Editor: Anti-interleukin 6 receptor (anti-IL-6R) antibodies have been effective in experimental models of autoimmune arthritis, encephalomyelitis, and also uveitis1,2. Tocilizumab (TCZ; RoActemra®, Hoffmann-La Roche, Basel, Switzerland), a fully humanized anti-IL-6R antibody, has been approved for the treatment of rheumatoid arthritis. Efficacy has also been shown for systemic-onset juvenile idiopathic arthritis (JIA)3 and vasculitis4. To date, however, no reports have appeared concerning its efficacy in JIA-associated uveitis. In about one-third of JIA patients with uveitis, eye inflammation runs a severe course and vision-threatening complications develop, and immunosuppressive treatment is required5. Because some patients do not respond properly to the widely used disease-modifying antirheumatic drugs (DMARD), including tumor necrosis factor-α (TNF-α) inhibitors, there is a significant need … Address correspondence to Dr. A. Heiligenhaus, Department of Ophthalmology and Ophtha Lab, St. Franziskus Hospital, Hohenzollernring 74, 48145 Münster, Germany. E-mail: arnd.heiligenhaus{at}uveitis-zentrum.deKeywords
This publication has 11 references indexed in Scilit:
- Safety and efficacy of tocilizumab, an anti-IL-6-receptor monoclonal antibody, in patients with polyarticular-course juvenile idiopathic arthritisModern Rheumatology, 2011
- Inhibition of IL6 in rheumatoid arthritis and juvenile idiopathic arthritisExperimental Cell Research, 2011
- Rapid induction of remission in large vessel vasculitis by IL-6 blockadeSwiss Medical Weekly, 2011
- Clinical value of blocking IL-6 receptorCurrent Opinion in Rheumatology, 2009
- Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitisRheumatology, 2009
- Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cellsNature, 2006
- Standardization of Uveitis Nomenclature for Reporting Clinical Data. Results of the First International WorkshopAmerican Journal of Ophthalmology, 2005
- IL-6 in autoimmune disease and chronic inflammatory proliferative diseaseCytokine & Growth Factor Reviews, 2002
- An evaluation of baseline risk factors predicting severity in juvenile idiopathic arthritis associated uveitis and other chronic anterior uveitis in early childhoodBritish Journal of Ophthalmology, 2002
- Performance of the preliminary definition of improvement in juvenile chronic arthritis patients treated with methotrexateAnnals of the Rheumatic Diseases, 1998